Hyperoside attenuates diabetic nephropathy by activating the Nrf2/SLC7A11/GPX4 axis to restrain ferroptosis

Figure 4 Hyperoside acts via Nrf2 to restrain ferroptosis (siRNA validation). ^aP < 0.05, ^bP < 0.01, ^dP < 0.001. One-way analysis of variance + Tukey’s post hoc test; two-sided. Data are expressed as the mean ± SD; n = 3 independent experiments. A: Quantitative reverse transcription-polymerase chain reaction confirming Nrf2 knockdown; B: Western blot confirming Nrf2 knockdown; C: Cell Counting Kit-8 time course: Small interfering RNA negative control, small interfering-Nrf2, and small interfering-Nrf2 + hyperoside (50 μM); D: Lipid reactive oxygen species detected using flow cytometry; E: Western blot analysis of Nrf2, SLC7A11, and GPX4 expression. si-NC: Small interfering RNA negative control; OD: Optical density; DCF: 2,7’-dichlorofluorescein; FITC-A: Fluorescein isothiocyanate-area.